QuidelOrtho (QDEL)
(Delayed Data from NSDQ)
$44.85 USD
+0.73 (1.65%)
Updated Sep 11, 2024 03:59 PM ET
After-Market: $45.07 +0.22 (0.49%) 5:14 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.85 USD
+0.73 (1.65%)
Updated Sep 11, 2024 03:59 PM ET
After-Market: $45.07 +0.22 (0.49%) 5:14 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
Zacks News
Ecolab (ECL) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
Although Ecolab's (ECL) third-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.
Is Quidel (QDEL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (QDEL) Outperforming Other Medical Stocks This Year?
What's in Store for IDEXX Laboratories (IDXX) in Q3 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) third-quarter top line is likely to have benefited from strength in CAG and LPD businesses.
Illumina (ILMN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is upbeat about its third-quarter sequencing consumable revenue growth.
Quidel (QDEL) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Quidel (QDEL) closed at $245.74 in the latest trading session, marking a +1.55% move from the prior day.
Quidel (QDEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Quidel (QDEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics' (DGX) Q3 Earnings Beat, Base Volume Rises
by Zacks Equity Research
In Q3, Quest Diagnostics (DGX) sees strong signs of the health care system returning to pre-pandemic levels
Align Technology (ALGN) Beats on Q3 Earnings, Margins Up
by Zacks Equity Research
Align Technology's (ALGN) segments report solid rebound in sales across geographies despite the pandemic-led business challenges.
Edwards Lifesciences (EW) Beats on Q3 Earnings, Margins Up
by Zacks Equity Research
Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q3.
Quidel, Akoustis Technologies, Netflix, Snap and Texas Instruments highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Quidel, Akoustis Technologies, Netflix, Snap and Texas Instruments highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Quidel (QDEL)
by Kevin Cook
Rapid COVID-19 tests that also screen influenza A+B have vaulted sales and profit growth 200-400%
Agios (AGIO) Withdraws Filing for Leukemia Drug Tibsovo in EU
by Zacks Equity Research
Agios (AGIO) withdraws the regulatory filing for Tibsovo in Europe, which was developed to treat relapsed/refractory acute myeloid leukemia in adult patients with a susceptible IDH1 mutation.
Top Ranked Momentum Stocks to Buy for October 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 16th
Top Ranked Momentum Stocks to Buy for October 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 8th
Big October Winners: CRISPR, Alteryx, NVIDIA, Quidel
by Kevin Cook
Two women will share the Nobel prize for a gene editing technology that will change the world.
Has Quidel (QDEL) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (QDEL) Outperforming Other Medical Stocks This Year?
Why the Earnings Surprise Streak Could Continue for Quidel (QDEL)
by Zacks Equity Research
Quidel (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Top Ranked Momentum Stocks to Buy for October 6th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 6th
7 Diagnostic and Genomic Stocks Storming Into October
by Kevin Cook
COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) witnessed revenue growth across two business segments in fiscal Q1.
Quidel (QDEL) Stock Moves -1.39%: What You Should Know
by Zacks Equity Research
Quidel (QDEL) closed at $196.21 in the latest trading session, marking a -1.39% move from the prior day.
NEOGEN (NEOG) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
NEOGEN's (NEOG) segmental revenues improve for the fiscal first quarter on strong sales of cleaners, disinfectants and sanitizers.
Rockwell Medical (RMTI) Soars: Stock Adds 9.7% in Session
by Zacks Equity Research
Rockwell Medical (RMTI) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Is Quidel (QDEL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (QDEL) Outperforming Other Medical Stocks This Year?
Quidel (QDEL) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Quidel (QDEL) closed the most recent trading day at $159.39, moving -1.12% from the previous trading session.